Lymphoma, Non-Hodgkin
Conditions
Brief summary
Describe the application status of different immunochemotherapies in small B-cell non-Hodgkin lymphoma (iNHL), observe the therapeutic efficacy and safety of the treatment modalities.
Detailed description
Evaluated the efficacy and safety of different immunochemotherapies in small B-cell non-Hodgkin lymphoma (iNHL)
Interventions
DRUGimmunochemotherapies
Observing different immunochemotherapies in small B-cell non-Hodgkin lymphoma (iNHL), which are chosen by investigators, such as RCHOP, BR, RCVP, etc.
Sponsors
Fudan University
Study design
Observational model
CASE_ONLY
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Age ≥ 18 years old * Initial or first recurrent iNHL confirmed by histopathology, including FL (1-3a), MZL, MCL; * Sign an informed consent form; * Researchers evaluate patients who can benefit from receiving immunochemotherapy.
Exclusion criteria
* There are contraindications to any medication in the treatment plan; * Pregnant or lactating women or male and female participants of childbearing age did not take contraceptive measures during the trial period and within 30 days after the last medication; * Researchers believe that patients who are not suitable for enrollment.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| ORR | up to 6 months | the ratio of numbers of patients with complete response and partial response to all the participants receiving treatment |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| 2-year progression-free survival (PFS) | From date of patients sign informed consent until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 2 years | the period from the date of patients sign informed consent to the observed progression of the disease or the occurrence of death for any reason |
| 2-year event-free survival (EFS) | From date of patients sign informed consent until the date of first documented event, progression or date of death from any cause, whichever came first, assessed up to 2 years | the period from the date of patients sign informed consent to the observed event for any reason |
| overall survival | From date of patients sign informed consent until the date of death or the date of last follow-up time, whichever came first, assessed up to 2 years | time between the date of patients sign informed consent and the date of death or the date of last follow-up time |
| Hematology and non hematology toxicity | Throughout the treatment period，up to 6 months | number of participants with treatment-related adverse events as assessed by CTCAE v5.0 |
Countries
China
Outcome results
None listed